Amgen, Inc. vs Endeavour Silver Corp — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Endeavour Silver Corp trades at $10.9 (market cap $3.14B). The key difference: Amgen, Inc. is far larger — about 71.4× Endeavour Silver Corp's market cap, and Amgen, Inc. pays a 2.43% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| AMGN | EXK | |
|---|---|---|
Market Cap | $224.14B | $3.14B |
Sector | Health | Basic Materials |
52-Week High | $417.20 | $14.12 |
52-Week Low | $271.18 | $5.31 |
Enterprise Value | $267.45B | $3.14B |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →